Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis
Taro Kishi, Yuki Matsuda, Nakao Iwata
Psychopharmacology (2017) Vol. 234, Iss. 14, pp. 2113-2125
Closed Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Thomas R. E. Barnes, Richard Drake, Carol Paton, et al.
Journal of Psychopharmacology (2019) Vol. 34, Iss. 1, pp. 3-78
Open Access | Times Cited: 505
Glutamate hypothesis in schizophrenia
Yota Uno, Joseph T. Coyle
Psychiatry and Clinical Neurosciences (2019) Vol. 73, Iss. 5, pp. 204-215
Open Access | Times Cited: 319
EPA guidance on treatment of negative symptoms in schizophrenia
Silvana Galderisi, Stefan Kaiser, István Bitter, et al.
European Psychiatry (2021) Vol. 64, Iss. 1
Open Access | Times Cited: 133
European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia
Antonio Vita, Wolfgang Gäebel, Armida Mucci, et al.
European Psychiatry (2022) Vol. 65, Iss. 1
Open Access | Times Cited: 85
Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia
William C. Hochberger, Yash B. Joshi, Michael L. Thomas, et al.
Neuropsychopharmacology (2018) Vol. 44, Iss. 3, pp. 606-612
Open Access | Times Cited: 56
Memantine in neurological disorders – schizophrenia and depression
Kamila Czarnecka, Jakub Chuchmacz, Przemysław Wójtowicz, et al.
Journal of Molecular Medicine (2021) Vol. 99, Iss. 3, pp. 327-334
Open Access | Times Cited: 36
Schizophrenia and Related Psychoses

(2025), pp. 1-278
Closed Access
The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis
Taro Kishi, Shinji Matsunaga, Nakao Iwata
Neuropsychiatric Disease and Treatment (2017) Vol. Volume 13, pp. 1909-1928
Open Access | Times Cited: 48
N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia
Joshua T. Kantrowitz
Schizophrenia Research (2018) Vol. 207, pp. 70-79
Closed Access | Times Cited: 41
Conceptualization and characterization of “primary” and “secondary” cognitive impairment in schizophrenia
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Psychiatry Research (2024) Vol. 340, pp. 116126-116126
Open Access | Times Cited: 4
Pharmacologic Augmentation of Computerized Auditory Training in Chronic Psychosis: Preliminary Findings From a Single-Site, Double-Blind Study
Neal R. Swerdlow, Joyce Sprock, Francesca Li, et al.
Schizophrenia Bulletin (2025)
Closed Access
Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge
Neal R. Swerdlow, Savita G. Bhakta, Gregory A. Light
Schizophrenia Research (2018) Vol. 199, pp. 285-291
Open Access | Times Cited: 37
Memantine effects on auditory discrimination and training in schizophrenia patients
Neal R. Swerdlow, Savita G. Bhakta, Jo Talledo, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 13, pp. 2180-2188
Open Access | Times Cited: 29
Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders
Michael Y. Bai, David B. Lovejoy, Gilles J. Guillemin, et al.
Complex Psychiatry (2021) Vol. 7, Iss. 1-2, pp. 19-33
Open Access | Times Cited: 25
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia
Tanja Veselinović, Irene Neuner
CNS Drugs (2022) Vol. 36, Iss. 8, pp. 819-858
Open Access | Times Cited: 17
Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations
Antonio Vita, Sergio Barlati, Roberto Cavallaro, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 3
Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate–Type Glutamate Receptor Function
Joshua T. Kantrowitz, Neal R. Swerdlow, Walter Dunn, et al.
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2018) Vol. 3, Iss. 7, pp. 581-590
Open Access | Times Cited: 28
Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis
Taro Kishi, Toshikazu Ikuta, Kazuto Oya, et al.
The International Journal of Neuropsychopharmacology (2018) Vol. 21, Iss. 8, pp. 748-757
Open Access | Times Cited: 28
Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
Tetsuro Kikuchi
Biomolecules (2020) Vol. 10, Iss. 8, pp. 1134-1134
Open Access | Times Cited: 26
Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review)
Octavia Căpățînă, I. Micluția, Mihaela Fadgyas Stănculete
Experimental and Therapeutic Medicine (2021) Vol. 21, Iss. 3
Open Access | Times Cited: 22
Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia
Borja Santos, Eduardo González–Fraile, Arantzazu Zabala, et al.
Journal of Psychopharmacology (2018) Vol. 32, Iss. 11, pp. 1155-1166
Closed Access | Times Cited: 26
Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia
Maju Mathew Koola
Complex Psychiatry (2018) Vol. 4, Iss. 3, pp. 134-148
Open Access | Times Cited: 26
Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials
Wei Zheng, Xiao-Min Zhu, Qing-E Zhang, et al.
Schizophrenia Research (2019) Vol. 209, pp. 12-21
Closed Access | Times Cited: 25
BDNF serum levels and cognitive improvement in drug-naive first episode patients with schizophrenia: A prospective 12-week longitudinal study
Zhi Wei Wu, Hui Shi, Da Chun Chen, et al.
Psychoneuroendocrinology (2020) Vol. 122, pp. 104879-104879
Closed Access | Times Cited: 20
Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia
Yash B. Joshi, Gregory A. Light
Frontiers in Psychiatry (2018) Vol. 9
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top